JP-CSPC@EC2609A

Stone Pharmaceutical Group's Injectable Paclitaxel Albumin Nanoparticle Receives FDA Clinical Trial Approval

Huatai Pacific 上调 Sino Pharm's 2027 and Beyond Revenue Forecast and Provided Target Price

Jinyao Group's Long-Acting Ropivacaine Injection Approved for Clinical Trials in China

Sino-Pharm Group's SYH2082 Approved for Clinical Trials

Nomura expects 20% revenue growth for Stone Pharmaceutical Group in Q4 2025 and 上调 profit forecast

New 纶威's Subsidiary Receives NMPA Approval for Clinical Trials of SYS6023

HSBC Research Raises Stone Pharmaceutical's Target Price and Rating

SinoPharm Group Enters into a $18.5 Billion Collaboration

CLSA Raises Target Price for Stone Pharmaceutical Group to HKD 19

Stone Pharmaceutical Group Obtains Registration Approval for Chlorverine Liposomal Injection from National Medical Products Administration

CICC: Stone Pharmaceutical Authorizes AstraZeneca for 8 Innovative Drug Projects

China Renaissance Sees Potential in Stone Pharmaceutical and AstraZeneca Deal, but More Details are Needed

Jade Pharmaceutical Group Reaches R&D Agreement with AstraZeneca, but Stock Price Drops

CICC Reiterates Buy Rating on Stone Pharmaceutical Group While TipRanks Downgrades

Jade Pharmaceutical and AstraZeneca Sign $18.5 Billion Collaboration Agreement

AstraZeneca Prepaid $1.2 Billion to Stone Pharmaceutical Group

Jade Harbour Group Signs Strategic R&D Collaboration and Licensing Agreement with AstraZeneca for Long-acting Peptide Drugs

Stone Pharmaceutical's In-body CAR-T Product SYS6055 Approved for Clinical Trials by NMPA

NeoWis Holdings' Subsidiary Receives Clinical Trial Approval for SYS6090 Injection

Sino-pharm Innovation Anticipates Net Loss in 2025 and Increases R&D Investment

CHINA OIL & GAS

PETRO-KING

DZUG

CHK OIL

MANY IDEA CLOUD

HAO TIAN INTL

JY GAS

COSCO SHIP DEV

GLOBAL UIN

BG BLUE SKY

159892

513700

520880

159849

159992

01093

510660

588130

513120

512290

159316

159570

159506

516500

562050

159837

512010

520500

CSPC Pharmaceutical Group has updated its board of directors, detailing roles of executive and independent non-executive directors, and clarifying the composition of its audit, nomination, and remuneration committees. This governance structure aims to enhance oversight and transparency, strengthening risk control and investor confidence in the regulated pharmaceutical sector. The latest analyst rating for CSPC stock (HK:1093) is a Hold with a price target of HK$10.70. The company has a market cap of HK$113.9B and a year-to-date price performance of 17.44%.

Tip Ranks

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

CSPC PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

CSPC Pharmaceutical Updates Board Composition and Committee Roles

159615

UBS released a research report listing investment ratings and target prices for healthcare stocks. Hengrui Pharma is rated as Buy, with the target price raised from RMB 96.9 to RMB 98.3; Hansoh Pharma is rated as Buy, with the target price raised from RMB 48.2 to RMB 51.5; Sino Biopharmaceutical is rated as Buy, with a target price of RMB 12.2; 3SBIO is rated as Buy, with a target price of RMB 41; CSPC Pharma is rated as Neutral, with the target price raised from RMB 10 to RMB 10.9; Simcere Pharma is rated as Buy, with a target price of RMB 16.3; United Lab is rated as Buy, with a target price of RMB 18.9

AASTOCKS

CSPC Innovation

Dacheng CSI All Share Health Care Equipment and Services ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI HK Equities Medical and Health Integration ETF

3SBIO

Huaan Hang Seng Biotech ETF

China Universal 800 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

HANSOH PHARMA

Founder Fubon CSI Medicine and Medical Device Innovation ETF

SIMCERE PHARMA

UNITED LAB

Tianhong CNI BIOMEDICINE ETF

Hengrui Pharma

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

SINO BIOPHARM

UBS Investment Ratings and Target Prices for Healthcare Stocks (Table)

CSPC PHARMA announced that its subsidiary, CSPC Innovation, will sell its non-core business - a 30.0704% stake in Beijing Guoxin Huijin, which operates a full media communication business platform, for a cash consideration of 230 million RMB. The estimated loss from the sale is approximately 15 million RMB

CSPC PHARMA's subsidiary sells core business for 230 million RMB

CSPC PHARMA issued a profit warning, expecting that the profit for the fiscal year 2025 will decrease by 45%-60% compared to the previous year's profit of 1.061 billion yuan. This is mainly due to the absence of large-scale epidemics domestically, coupled with medical insurance cost control leading to a decline in terminal sales of drugs, the expansion of the scope of volume-based procurement, and intensified domestic and international industry competition resulting in sustained price pressure, as well as the fact that the bromhexine hydrochloride injection will no longer be sold through the national drug procurement

"Profit Warning" CSPC PHARMA's revenue declines, expects to earn 45%-60% less for the year

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy

marketscreener

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy

CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China

CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China

CSPC PHARMA's SYH2082 injection has been approved by the U.S. FDA, allowing for clinical trials in the United States. This drug is a GLP-1/GIP receptor dual biased agonist, designed to enhance efficacy and prolong action time by selectively activating the cAMP pathway. Combined with long half-life modifications and long-acting formulation technology, the goal is to achieve sustained weight loss

CSPC PHARMA's SYH2082 injection approved for clinical use in the United States

CSPC PHARMA announced that the long-acting injection of ropivacaine (SYH 9089 injection) developed by the group has been approved by the National Medical Products Administration and can conduct clinical trials in China. The group stated that through its long-acting drug delivery technology platform, this product can extend the duration of analgesia from a single dose to one week, and is expected to become China's first ultra-long-acting analgesic product with a duration of one week

CSPC PHARMA SYH 9089 injection approved for clinical use in China

CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials

CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials

Nomura raised the target price for CSPC PHARMA to RMB 12.04, maintaining a "Buy" rating. It is expected that revenue in the fourth fiscal quarter of 2025 will grow by 20% to RMB 7.6 billion, slightly above market expectations. The gross margin is expected to increase to 68.5%, with a net profit of RMB 1.3 billion. For the fiscal year 2026, revenue is expected to increase by 14% to RMB 31.2 billion, and profit is expected to rise by 39% to RMB 6.7 billion

Nomura raises CSPC PHARMA's target price to 12.04 yuan, maintains "Buy" rating

CSPC Pharmaceutical Group Ltd. announced a record $18.5 billion licensing deal with AstraZeneca, but its stock fell sharply by over 10% following the news. The deal, which includes rights to CSPC's anti-obesity drugs, was anticipated to boost CSPC's global market presence. However, investor disappointment stemmed from high expectations set by prior rumors, leading to a sell-off. Concerns about CSPC's corporate governance, following an insider trading case, may have further impacted investor confidence. The company is under pressure as its core drug business faces challenges from China's procurement policies.

benzinga_article

AstraZeneca PLC

AstraZeneca

Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca

002422

06990

01801

Mainland Chinese investors have increased their investments in Hong Kong-listed drug stocks, with the Hang Seng Southbound Connect Hong Kong Innovative Drug Index rising about 9% recently. CSPC Pharmaceutical Group and Sichuan Kelun-Biotech saw significant gains. Innovent Biologics announced a major collaboration with Eli Lilly worth up to $8.85 billion, enhancing its drug development process. This trend reflects a shift in how Chinese drug makers engage with global partners, as they gain more control over the development of their medicines amid a competitive pharmaceutical landscape.

南华早报

KELUN PHARMA

SKB BIO-B

Eli Lilly

INNOVENT BIO

iShares US Pharma

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Tibet Dongcai CSI Hugangshen Innovative Drugs Industry ETF

ICBCCS CNI HK Connect Innovative Drugs ETF

Yinhua CNI HK Connect Innovative Drugs ETF

Mainland China’s investors pour into Hong Kong-listed drug stocks

02513

01072

09992

01818

03986

09980

01880

03690

KNOWLEDGE ATLAS(02513) rose 14.81%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 173.5%. DONGFANG ELEC(01072) rose 7.11%, with a trading turnover 810.9 Million HKD, and a year-to-date rose 23%. ZHAOJIN MINING(01818) fell 5.83%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 6.1%. GIGADEVICE(03986) fell 3.82%, with a trading turnover 252.3 Million HKD, and a year-to-date rose 86.4%.

- The Hang Seng Index increased by 0.58%, with a year-to-date rise of 6.1%.  
- The Hang Seng Tech Index rose 0.62%, but has declined 1.2% for the year.  
- Stocks like Zhihua (02513) surged by 14.81% and recorded a significant yearly gain of 173.5%, while stocks like Zhaojin Mining (01818) dropped by 5.83% despite a yearly increase of 6.1%.

Top Gainers & Losers

KNOWLEDGE ATLAS

DONGFANG ELEC

POP MART

ZHAOJIN MINING

GIGADEVICE

EASTROC

CTG DUTY-FREE

MEITUAN

Top 5 HK Stock Gainers/Losers (>100B) (2.10)

Hot trading industry trends on August 7 and related Hong Kong semiconductor stocks. Hong Kong semiconductor stocks opened lower in early trading but then surged strongly, with Innoscience gaining over 11%, and industry leader SMIC rising over 3%. Core logic: On the news front, on August 1, Innoscience officially responded to rumors of collaboration with NVIDIA. The announcement stated that the company has recently partnered with global AI technology leader NVIDIA to jointly promote the large-scale implementation of the 800VDC (800-volt direct current) power architecture in AI data centers. Clear signals of a cyclical bottom: Global semiconductor inventory reduction is nearing its end...

NVIDIA

SMIC

SMIC HK SDR 5to1

SJM HOLDINGS

MGM CHINA

FIT HON TENG

WUXI APPTEC

WuXi AppTec

INNOCARE

InnoCare Pharma

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

GALAXY ENT

Galaxy Entertainment Group

NAGACORP

WYNN MACAU

MELCO INT'L DEV

SANDS CHINA LTD

Sands China

COWELL

HUA HONG SEMI

Hua Hong

SHANGHAI FUDAN

FMSH

INNOSCIENCE

SOLOMON SYSTECH

TIGERMED

Tigermed

Apple

Hot Trades in Hong Kong Stocks (8.7)｜ Chip Stocks Rebound Strongly, Apple Supply Chain Follows; Xiaomi and Pharmaceuticals Retreat Under Pressure

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

HENGRUI PHARMA

OSL GROUP

CPIC

SUNSHINE INS

CR HOLDINGS

CHINA LIFE

China Life

GUOTAI JUNAN I

AIA-R

AIA Group

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

JP-CSPC@EC2609A(25511.HK)

CSPC Pharmaceutical Updates Board Composition and Committee Roles

UBS Investment Ratings and Target Prices for Healthcare Stocks (Table)

CSPC PHARMA's subsidiary sells core business for 230 million RMB

"Profit Warning" CSPC PHARMA's revenue declines, expects to earn 45%-60% less for the year

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy